FL-BRIGHTSTAR/KII
13.5.2015 00:01:42 CEST | Business Wire | Pressemeddelelse
Brightstar , a SoftBank subsidiary and the world’s largest specialized wireless distributor and leader in innovation and diversified services for the wireless industry, and Kii , a leading mobile and IoT back-end platform provider, today announced a partnership to better connect the IoT market by creating a global ecosystem supporting the development and distribution of IoT products into retail and mobile operator channels.
The new ecosystem, dubbed “Space: The Infinity of Things™,” is open to all IoT players from manufacturers and developers to retailers and mobile operators. Manufacturers who want to sell their IoT devices globally can leverage Brightstar’s worldwide network to establish new points of entry. Developers working with the open IoT platform will have access across all devices, operating systems, and chipsets, allowing them to create innovative new applications and services for IoT devices more quickly. For mobile operators and retailers who want to jointly source connected products, the open IoT ecosystem offers the benefits of scale to bring their products to market more quickly and opens new business opportunities.
“Brightstar’s expertise in wireless distribution and specialized services is unparalleled and we are in the ideal position to facilitate collaboration in the IoT market within the mobile industry,” said Atsushi Taira, Brightstar’s Chief Planning and Optimization Officer. "Our goal is to accelerate the go-to-market process of these innovative products by connecting operators and retailers with the right mix of IoT devices at affordable price points for consumers.”
"We’re providing device manufacturers, service providers and developers with all the enabling tools and services they need to quickly and economically build successful connected solutions from the idea/prototyping stage all the way to production operation and then Brightstar can manage their distribution," said Masanari Arai, CEO of Kii.
Device manufacturers are building smart products at an unprecedented pace, but the process for getting them into customer hands is slow and inefficient. Architecting underlying systems and services for production-grade, interconnected IoT initiatives is complex, costly and time consuming. Brightstar and Kii will accelerate this process and drive IoT innovation by creating an accessible ecosystem and an open platform for development.
Due to a partnership between Kii and the Alibaba IoT Cloud Division in China, devices that deploy under the open IoT platform can enjoy full interoperability on the Alibaba IoT Cloud. Device manufacturers can give their IoT devices global cloud access through a single deployment through “Space” to sell in China and the rest of the world.
“Much of the success of smart devices and IoT solutions hinges not just on the devices themselves, but on making them available to consumers in the right retail setting,” Taira said. “As smartphones reach a saturation point in many markets, operators are diversifying their portfolio from smartphones and tablets to include lifestyle enhancing products such as connected home and mobile health devices.”
Through the open ecosystem, Brightstar is currently working with prominent operators and retailers such as SoftBank Mobile, LG U+ and Shinsegae. Additionally, Brightstar and Kii are working with information and communications technology distributors such as SBCK Corp. and SoftBank Commerce & Service Corp.
Brightstar and Kii will be also working with international manufacturers such as Toshiba, YanKon, ThroughTek, Liquid Image, iFit® , Rooti, Fineck, Toymail, Haltian, Mozbii, Leeo, Astak and Kenzenwear to bring products to market more efficiently for consumers.
For more information, visit iotspace.org .
About Brightstar
Brightstar is the world’s largest specialized wireless distributor and a leading provider of diversified services focused on enhancing the performance and results of the key participants in the wireless device value chain: manufacturers, operators and retailers. In 2014, Brightstar reported global net revenues of more than $10 billion and employs about 9,000 people on six continents. For more information, please visit Brightstar.com.
About Kii
Kii is focused on addressing the high-performance demands of innovation in the connected world with an end-to-end backend platform optimized for Internet of Things (IoT) and mobile applications. Businesses of all sizes are able to build, test, deploy, manage, optimize and acquire users from a single integrated platform to accelerate time to market. Trusted by the world's largest device manufacturers and mobile carriers such as NTT Docomo, Kii currently serves 140M+ end users worldwide. Kii is a global company with data centers in the US, China and Japan. For more information, follow @KiiCorp or visit kii.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150512006657/en/
Contact:
Brightstar
Erik Hofmeyer, 305-921-1258
Erik.Hofmeyer@brightstar.com
@Brightstar
OR
Kii
Lauren
Epstein, 212-334-9753, ext. 117
North 6th Agency, Inc.
lepstein@n6a.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum